An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne

References

• Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–485.
   PubMed Web of Science ®Google Scholar
• Schafer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol. 2001;145(1):100–104.
   PubMed Web of Science ®Google Scholar
• Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002;138(12):1584–1590.
   PubMedGoogle Scholar
• Leyden J. Recent advances in the use of adapalene 0.1%/benzoyl peroxide 2.5% to treat patients with moderate to severe acne. J Dermatolog Treat. 2016;27(1):S4–13.
   PubMed Web of Science ®Google Scholar
• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–73 e33.
   PubMed Web of Science ®Google Scholar
• Dunn LK, O’Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J. 2011;17(1):1.
   PubMedGoogle Scholar
• Tan JK, Li Y, Fung K, et al. Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. J Cutan Med Surg. 2008;12(5):235–242.
   PubMed Web of Science ®Google Scholar
• Krejci-Manwaring J, McCarty MA, Camacho F, et al. Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol. 2006;54(5):S235–6.
   PubMedGoogle Scholar
• Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86(2):103–108.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327–348.
   PubMed Web of Science ®Google Scholar
• Chien A. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12):s51–5.
   Web of Science ®Google Scholar
• Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis. 2008;82(6):417–421.
   PubMed Web of Science ®Google Scholar
• Tolaymat L, Zito PM Adapalene. statpearls. Treasure Island (FL) 2021.
   Google Scholar
• Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol. 1997;36(6):S119–25.
   PubMed Web of Science ®Google Scholar
• Merker PC. Benzoyl peroxide: a history of early research and researchers. Int J Dermatol. 2002;41(3):185–188.
   PubMed Web of Science ®Google Scholar
• World Health Organization Model List of Essential Medicines. 21st List, 2019. Geneva: World Health Organization; 2019.
   Google Scholar
• Matin T, Goodman MB Benzoyl peroxide. StatPearls. Treasure Island (FL) 2021.
   Google Scholar
• Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol. 1998;39(2):S17–24.
   PubMed Web of Science ®Google Scholar
• Martin B, Meunier C, Montels D, et al. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(Suppl 52):8–11.
   PubMed Web of Science ®Google Scholar
• Epiduo (adapalene and benzoyl peroxide) gel, 0.1%/2.5% prescribing information. Silver Spring, MD: U.S. Food and Drug Administration; 2008.
   Google Scholar
• Epiduo Forte (adapalene and benzoyl peroxide) gel. 0.3%/2.5% prescribing information. Silver Spring, MD: U.S. Food and Drug Administration; 2015.
   Google Scholar
• Piskin S, Uzunali E. A review of the use of adapalene for the treatment of acne vulgaris. Ther Clin Risk Manag. 2007;3(4):621–624.
   PubMedGoogle Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the drugbank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D82.
   PubMed Web of Science ®Google Scholar
• PubChem Compound Summary for CID 60164, Adapalene [Internet]. National Center for Biotechnology Information. [cited 2021 Mar 17]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Adapalene.
   Google Scholar
• PubChem Compound Summary for CID 7187, Benzoyl peroxide [Internet]. national center for biotechnology information. [cited 2021 Mar 17]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Benzoyl-peroxide.
   Google Scholar
• Sato T, Akimoto N, Kitamura K, et al. Adapalene suppresses sebum accumulation via the inhibition of triacylglycerol biosynthesis and perilipin expression in differentiated hamster sebocytes in vitro. J Dermatol Sci. 2013;70(3):204–210.
   PubMed Web of Science ®Google Scholar
• Tan J, Gollnick HP, Loesche C, et al. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat. 2011;22(4):197–205.
   PubMed Web of Science ®Google Scholar
• Waugh J, Noble S, Scott LJ. Adapalene: a review of its use in the treatment of acne vulgaris. Drugs. 2004;64(13):1465–1478.
   PubMed Web of Science ®Google Scholar
• Yeung D, Nacht S, Bucks D, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. II. Effect of concentration. J Am Acad Dermatol. 1983;9(6):920–924.
   PubMed Web of Science ®Google Scholar
• A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris [Internet]. U.S. National Library of Medicine. 2007. [cited 2021 Mar 9]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00421993.
   Google Scholar
• Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % topical gel in acne vulgaris [Internet]. U.S. National Library of medicine. 2013. [cited 2021 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01880320.
   Google Scholar
• Stein Gold L, Weiss J, Rueda MJ, et al. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17(3):293–303.
   PubMed Web of Science ®Google Scholar
• Dréno B, Tan J, Rivier M, et al. Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial. J Eur Acad Dermatol Venereol. 2017 Apr;31(4):737–742.
   PubMed Web of Science ®Google Scholar
• Dréno B, Bissonnette R, Gagné-Henley A, et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison. Am J Clin Dermatol. 2018 Apr;19(2):275–286.
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(Suppl 52):48–56.
   PubMed Web of Science ®Google Scholar
• Fakhouri T, Yentzer BA, Feldman SR. Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. J Drugs Dermatol. 2009;8(7):657–661.
   PubMed Web of Science ®Google Scholar
• Epiduo Forte (adapalene/benzoyl peroxide, 0.3%/2.5%) gel pediatric postmarketing pharmacovigilance review. U.S. Food and Drug Administration; 2017.
   Google Scholar
• Myhill T, Coulson W, Nixon P, et al. Use of supplementary patient education material increases treatment adherence and satisfaction among acne patients receiving adapalene 0.1%/benzoyl peroxide 2.5% gel in primary care clinics: a multicenter, randomized, controlled clinical study. Dermatol Ther (Heidelb). 2017 Dec 7;7(4):515–524.
   PubMed Web of Science ®Google Scholar
• Donnarumma M, Fattore D, Greco V, et al. How to increase adherence and compliance in acne treatment? A combined strategy of SMS and visual instruction leaflet. Dermatology. 2019;235(6):463–470.
   PubMed Web of Science ®Google Scholar
• Fabbrocini G, Izzo R, Donnarumma M, et al. Acne smart club: an educational program for patients with acne. Dermatology. 2014;229(2):136–140.
   PubMed Web of Science ®Google Scholar
• Zhang N, Yuan R, Xin KZ, et al. Antimicrobial susceptibility, biotypes and phylotypes of clinical Cutibacterium (formerly Propionibacterium) acnes strains isolated from acne patients: an observational study. Dermatol Ther. 2019;9(4):735–746.
   Google Scholar
• Alkhawaja E, Hammadi S, Abdelmalek M, et al. Antibiotic resistant Cutibacterium acnes among acne patients in Jordan: a cross sectional study. BMC Dermatol. 2020;20(1):17.
   PubMed Web of Science ®Google Scholar
• Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol. 1996;134(1):107–113.
   PubMed Web of Science ®Google Scholar
• Gold LS, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis. 2010 Feb;85(2):94–104.
   PubMed Web of Science ®Google Scholar
• Dréno B, Kaufmann R, Talarico S, et al. Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. Br J Dermatol. 2011 Aug;165(2):383–390.
   PubMed Web of Science ®Google Scholar
• Felix K, Unrue E, Inyang M, et al. Patients preferences for different corticosteroid vehicles are highly variable. J Dermatolog Treat. 2020;31(2):147–151.
   PubMed Web of Science ®Google Scholar